All In Biotech

Drug Trial Radar · NCT05943886

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

Last checked: Nov 19, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

164

Actual

Start

Aug 11, 2021

Primary completion

Feb 17, 2023

Study completion Feb 17, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).

Conditions

  • Healthy Subjects
  • Obesity
  • T2DM (Type 2 Diabetes Mellitus)

Interventions

  • HEC88473 injectionDrug

    HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.

  • PlaceboDrug

    Placebo will be administered by subcutaneous injection in the abdomen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473Time frame: Baseline to day 15
  2. Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473Time frame: Baseline to day 43
  3. CmaxTime frame: Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours
  4. AUCTime frame: Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.